Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

1.3K

https://thehotstar.net/separatebatches.html

What can be made of this?

Well in summary, it has been demonstrated to be known that the mRNA gene therapy vaccine solution can be produced using two substantively different processes, a clinical process and a commercial process. It has been demonstrated to be known that commercial batches have a higher potential for risk than clinical batches. It has been demonstrated to be known that the EMA expressed concerns with Pfizer over discrepancies between the clinical and commercial batches, pertinent to the safety and efficacy of the mRNA gene therapy vaccine solution produced. It is has been demonstrated to be known that Pfizer and Pfizer corporate associates vaccinate their employees and their employees families with batches that are separate from commercial batches given to the general population. It is reasonable to believe that data provided by Untied States post market surveillance system, VAERS, may indicate an extremely uneven distribution of reported incidents of AE and death across batches of the mRNA gene therapy vaccine solution, indicating some batches are significantly more risky than others. It has been demonstrated to be known, that at least in Australia, Pfizer employee batches are not tested by the National regulatory agency which tests all commercial batches, and that batches marked for Pfizer employees in Australia underwent odd modifications as to their regulatory status and use within the country.

Based on the totality of evidence, it is reasonable to believe that specific batches of the mRNA gene therapy vaccine solution produced using commercial batch process 2 may lead to substantially higher reports of adverse events and death than batches of the mRNA gene therapy vaccine substance produced using clinical batch process 1. If this is reasonable to believe, then it would reasonably follow those aware of the increased risk of commercial batches, would seek to reduce this risk through administering a mRNA gene therapy vaccine solution from a clinical batch to themselves and families.

Whether or not this is true, I do not know.

https://thehotstar.net/separatebatches.html >What can be made of this? > Well in summary, it has been demonstrated to be known that the mRNA gene therapy vaccine solution can be produced using two substantively different processes, a clinical process and a commercial process. It has been demonstrated to be known that commercial batches have a higher potential for risk than clinical batches. It has been demonstrated to be known that the EMA expressed concerns with Pfizer over discrepancies between the clinical and commercial batches, pertinent to the safety and efficacy of the mRNA gene therapy vaccine solution produced. It is has been demonstrated to be known that Pfizer and Pfizer corporate associates vaccinate their employees and their employees families with batches that are separate from commercial batches given to the general population. It is reasonable to believe that data provided by Untied States post market surveillance system, VAERS, may indicate an extremely uneven distribution of reported incidents of AE and death across batches of the mRNA gene therapy vaccine solution, indicating some batches are significantly more risky than others. It has been demonstrated to be known, that at least in Australia, Pfizer employee batches are not tested by the National regulatory agency which tests all commercial batches, and that batches marked for Pfizer employees in Australia underwent odd modifications as to their regulatory status and use within the country. > Based on the totality of evidence, it is reasonable to believe that specific batches of the mRNA gene therapy vaccine solution produced using commercial batch process 2 may lead to substantially higher reports of adverse events and death than batches of the mRNA gene therapy vaccine substance produced using clinical batch process 1. If this is reasonable to believe, then it would reasonably follow those aware of the increased risk of commercial batches, would seek to reduce this risk through administering a mRNA gene therapy vaccine solution from a clinical batch to themselves and families. > Whether or not this is true, I do not know.

(post is archived)

You are currently inside a comment thread.
Click here to see all the comments (5).
[–] • 1 pt

If I can find them again. I posted the original links on the Pfizer whistleblower and the Japanese lab results on here a few months ago.